BACKGROUND: Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting. METHODS: In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors. RESULTS: Thirty-two patients were enrolled. Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression-free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3-4 neutropenia in 5 (15.6%) patients. CONCLUSIONS: In this trial CE regimen has shown relevant activity with a favourable safety profile.
BACKGROUND:Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary. We decided to determine the efficacy and toxicity profile of the carboplatin and etoposide (CE) regimen in this setting. METHODS: In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors. RESULTS: Thirty-two patients were enrolled. Median age was 42 years (range 22-66); median ECOG PS was 0 (range 0-2); 9 patients had oligodendroglioma, 3 patients had oligoastrocytoma, 11 patients had anaplastic oligodendroglioma, 9 patients had anaplastic oligoastrocytoma. CE regimen showed a response rate of 46.9% with 5 complete responses (15.6%) and 10 partial responses (31.3%). Eleven patients (34.4%) had stable disease. Median time to progression was 8 months, progression-free survivals at 6 and 12 months were 80% and 46.9%, respectively. Toxicity was mainly hematological, with grade 3-4 neutropenia in 5 (15.6%) patients. CONCLUSIONS: In this trial CE regimen has shown relevant activity with a favourable safety profile.
Authors: Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: J C Buckner; L D Brown; T L Cascino; J B Gerstner; J E Krook; M W Westberg; M Wiesenfeld; J R O'Fallon; B Scheithauer Journal: J Neurooncol Date: 1990-12 Impact factor: 4.130
Authors: O L Chinot; S Honore; H Dufour; M Barrie; D Figarella-Branger; X Muracciole; D Braguer; P M Martin; F Grisoli Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: M J van den Bent; J M Kros; J J Heimans; L C Pronk; C J van Groeningen; H G Krouwer; M J Taphoorn; B A Zonnenberg; C C Tijssen; A Twijnstra; C J Punt; W Boogerd Journal: Neurology Date: 1998-10 Impact factor: 9.910
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Brian V Nahed; Navid Redjal; Daniel J Brat; Andrew S Chi; Kevin Oh; Tracy T Batchelor; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: J Neurooncol Date: 2015-11-03 Impact factor: 4.130